The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

Scientists uncover a new “recipe” that shows how exhausted T cells can be reprogrammed to regain their ability to attack tumors.

New therapy reprograms immune cells inside tumors to attack cancer, bypassing traditional cell therapy manufacturing ...

A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...

Up to 20% of hormone receptor-positive breast cancers don't respond to antiestrogen therapies. A study led by researchers at ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...

New research shows lymph nodes aren’t just cancer bystanders, they’re the command centers fueling immune attacks. Surgically removing them along with tumors may weaken treatment, while preserving them ...